Tuesday, June 13, 2023
Neuronetics, Inc., a publicly traded medical technology company (NASDAQ: STIM), specializes in the development and marketing of products aimed at improving the quality of life for individuals with neurohealth disorders. Recently, the company announced that it has obtained 510(k) clearance from the FDA for its OCD MT Cap technology, designed for use in NeuroStar Advanced Therapy for Mental Health.
Cory Anderson, Senior Vice President of R&D and Clinical at Neuronetics, emphasized the company's commitment to delivering the latest technology that simplifies the treatment process for their customers. The OCD MT Cap's unique design and functionality allow clinicians to optimize treatment efficiency while upholding the highest standard of patient care. Anderson also highlighted how this innovation positions NeuroStar for upcoming technological advancements expected in the near future.
The Motor Threshold (MT) plays a crucial role in establishing the appropriate treatment prescription for patients. NeuroStar stands out as the sole TMS system with FDA clearance for MT Caps designed for both obsessive-compulsive disorder (OCD) and major depressive disorder (MDD). The OCD MT Cap simplifies the initial coil placement by providing a consistent starting location and a step-by-step process to map the patient's motor cortex, reducing time and complexity. It shares the same advantages as the existing MT Cap for MDD, including compatibility with Fast MT™, resulting in significant time savings for both clinicians and patients during the initial visit.
Dr. Kenneth Pages, Medical Director at TMS of South Tampa, expressed excitement about the FDA-cleared MT Cap for OCD, acknowledging its numerous benefits based on his firsthand experience. He emphasized that this new technology will empower his practice to deliver effective and personalized care for individuals struggling with OCD.
NeuroStar has already treated nearly 300 OCD patients, delivering over 6,000 treatments. The OCD MT Cap will initially be available at select sites this month, with nationwide availability expected in the fourth quarter. For more information about NeuroStar, please visit their official website at NeuroStar.com.
https://www.globenewswire.com/news-release/2023/06/12/2686330/0/en/Neuronetics-Receives-510-k-Clearance-for-OCD-MT-Cap-for-NeuroStar-Advanced-Therapy.html
